MX2023000004A - Formulaciones para promover la hidratacion y metodos de uso de las mismas. - Google Patents
Formulaciones para promover la hidratacion y metodos de uso de las mismas.Info
- Publication number
- MX2023000004A MX2023000004A MX2023000004A MX2023000004A MX2023000004A MX 2023000004 A MX2023000004 A MX 2023000004A MX 2023000004 A MX2023000004 A MX 2023000004A MX 2023000004 A MX2023000004 A MX 2023000004A MX 2023000004 A MX2023000004 A MX 2023000004A
- Authority
- MX
- Mexico
- Prior art keywords
- barrier function
- intestinal barrier
- formulations
- need
- hydration
- Prior art date
Links
- 230000036571 hydration Effects 0.000 title abstract 5
- 238000006703 hydration reaction Methods 0.000 title abstract 5
- 238000009472 formulation Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 230000001737 promoting effect Effects 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 230000007358 intestinal barrier function Effects 0.000 abstract 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
- 230000018044 dehydration Effects 0.000 abstract 3
- 238000006297 dehydration reaction Methods 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 230000001771 impaired effect Effects 0.000 abstract 3
- 239000004469 amino acid formulation Substances 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Formulaciones que comprenden aminoácidos libres específicos útiles para promover la hidratación y/o la función de barrera intestinal en un sujeto que lo necesita se describen en el presente documento. Dichas formulaciones y métodos usando los mismos son útiles para promover la hidratación y/o la función de barrera intestinal en un sujeto que lo necesite. Dichos sujetos pueden estar sanos, pero con la necesidad de una formulación que promueva la hidratación rápida (por ejemplo, dentro de los siguientes 15-90 minutos después de la administración) o promueve la función de la barrera intestinal; o dichos sujetos se pueden ver afectados por una padecimiento o enfermedad asociada con la deshidratación o la función de barrera intestinal alterada, respectivamente. El uso de formulaciones de aminoácidos descritas en el presente documento para promover la hidratación y/o la función de barrera intestinal en un sujeto que lo necesita, para el tratamiento de trastornos o enfermedades asociadas con la deshidratación y/o la función de barrera intestinal alterada, y en la preparación de un medicamento para el tratamiento de trastornos o enfermedades asociadas con la deshidratación y/o la función de barrera intestinal alterada se incluyen en el presente documento.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063047300P | 2020-07-02 | 2020-07-02 | |
| PCT/US2021/040090 WO2022006397A1 (en) | 2020-07-02 | 2021-07-01 | Formulations for promoting hydration and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023000004A true MX2023000004A (es) | 2023-03-06 |
Family
ID=79314908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023000004A MX2023000004A (es) | 2020-07-02 | 2021-07-01 | Formulaciones para promover la hidratacion y metodos de uso de las mismas. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230149335A1 (es) |
| EP (1) | EP4175662A4 (es) |
| JP (1) | JP2023533617A (es) |
| KR (1) | KR20230047371A (es) |
| CN (1) | CN116194136A (es) |
| AU (1) | AU2021300188A1 (es) |
| BR (1) | BR112022027124A2 (es) |
| CA (1) | CA3184691A1 (es) |
| IL (1) | IL299488A (es) |
| MX (1) | MX2023000004A (es) |
| WO (1) | WO2022006397A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11878073B1 (en) * | 2022-09-20 | 2024-01-23 | Entrinsic, LLC | Generation of hydration-targeted formulations and methods of use therein |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3916903A1 (de) * | 1989-05-24 | 1991-02-28 | Leopold Pharma Gmbh | Waessrige zusammensetzung fuer die parenterale ernaehrung |
| JP2002275059A (ja) * | 2001-03-15 | 2002-09-25 | Inst Of Physical & Chemical Res | 腎機能障害改善用アミノ酸組成物 |
| WO2010017403A2 (en) * | 2008-08-06 | 2010-02-11 | Immunopath Profile, Inc. | Therapeutic compositions, devices and methods for observing treated tissues |
| WO2010041647A1 (ja) * | 2008-10-06 | 2010-04-15 | 明治乳業株式会社 | アミノ酸組成物を有効成分として含む持久力向上剤、疲労防止剤、又は疲労回復剤 |
| KR102205124B1 (ko) * | 2010-09-24 | 2021-01-20 | 유니버시티 오브 플로리다 리서치 파운데이션, 인크. | 위장 기능을 증진시키기 위한 물질 및 방법 |
| AP3941A (en) * | 2012-02-08 | 2016-12-16 | Univ Florida | Materials and methods for treating diarrhea |
| EP3459540A1 (en) * | 2014-11-24 | 2019-03-27 | Entrinsic Health Solutions, Inc. | Amino acid compositions for the treatment of symptoms of disease |
| CN110062621B (zh) * | 2016-10-04 | 2022-11-01 | 佛罗里达大学研究基金会公司 | 氨基酸组合物及其用途 |
| WO2019070753A1 (en) * | 2017-10-02 | 2019-04-11 | University Of Florida Research Foundation, Incorporated | AMINO ACID COMPOSITIONS AND METHODS FOR TREATING DIARRHEA |
-
2021
- 2021-07-01 KR KR1020237003742A patent/KR20230047371A/ko unknown
- 2021-07-01 BR BR112022027124A patent/BR112022027124A2/pt unknown
- 2021-07-01 CA CA3184691A patent/CA3184691A1/en active Pending
- 2021-07-01 IL IL299488A patent/IL299488A/en unknown
- 2021-07-01 JP JP2023524492A patent/JP2023533617A/ja active Pending
- 2021-07-01 CN CN202180056268.5A patent/CN116194136A/zh active Pending
- 2021-07-01 WO PCT/US2021/040090 patent/WO2022006397A1/en active Application Filing
- 2021-07-01 MX MX2023000004A patent/MX2023000004A/es unknown
- 2021-07-01 EP EP21834528.8A patent/EP4175662A4/en active Pending
- 2021-07-01 AU AU2021300188A patent/AU2021300188A1/en active Pending
-
2022
- 2022-12-30 US US18/148,903 patent/US20230149335A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL299488A (en) | 2023-02-01 |
| WO2022006397A1 (en) | 2022-01-06 |
| EP4175662A4 (en) | 2024-07-17 |
| CN116194136A (zh) | 2023-05-30 |
| KR20230047371A (ko) | 2023-04-07 |
| JP2023533617A (ja) | 2023-08-03 |
| AU2021300188A1 (en) | 2023-02-02 |
| CA3184691A1 (en) | 2022-12-30 |
| BR112022027124A2 (pt) | 2023-03-07 |
| EP4175662A1 (en) | 2023-05-10 |
| US20230149335A1 (en) | 2023-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Russo et al. | Clinical efficacy of injection and mechanical therapy for Peyronie's disease: a systematic review of the literature | |
| MX2019011215A (es) | Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos. | |
| SG162788A1 (en) | Self-buffering protein formulations | |
| Fidler et al. | Slipped upper femoral epiphysis following treatment with human growth hormone | |
| MX2017001682A (es) | Composiciones de alergenos alimentarios. | |
| MX2018003352A (es) | Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer. | |
| MX2023010328A (es) | Composiciones de medicamentos a base de peptido de colageno y metodos y dispositivos para su produccion y uso. | |
| DK1401422T3 (da) | Halogenholdig sammensætning, fremgangsmåde til fremstilling heraf og anvendelser heraf | |
| MX2020010130A (es) | Formulacion y metodo de preparacion. | |
| HUP0102479A2 (hu) | Neisseria meningitidis-ből származó BASBO29-polinukleotid(ok) és polipeptidek | |
| Wollina et al. | Disabling pansclerotic morphea of childhood poses a high risk of chronic ulceration of the skin and squamous cell carcinoma | |
| MX2023000004A (es) | Formulaciones para promover la hidratacion y metodos de uso de las mismas. | |
| Bali et al. | Cyclosporine reduces sclerosis in morphea: a retrospective study in 12 patients and a literature review | |
| Brazzelli et al. | Bleomycin-induced flagellate dermatitis: report of four paediatric cases. | |
| Dębowska et al. | Evaluation of the efficacy and tolerability of mandelic acid-containing cosmetic formulations for acne skin care | |
| WO2019055776A3 (en) | Compositions and methods for treatment of diseases involving cxcl1 function | |
| BR0213656A (pt) | composição, método para a obtenção de uma resposta imune à tênia, método para vacinar um mamìfero contra tênia, vacina, método para pemitir a vacinação, métodos para a redução de perda sangüìnea, para a redução do tamanho da tênia e para a redução de aflição por tênia em um paciente infectado com tênia, antìgeno recombinante sintético e antìgeno | |
| JOP20200046A1 (ar) | طرق لعلاج أمراض مرتبطة بـtnf? | |
| MX2024005052A (es) | Composicion farmaceutica y kit que comprende una sustancia inmunomoduladora para tratar enfermedades. | |
| UY39083A (es) | Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
| Dalewski et al. | Clinical Study Comparison of Early Effectiveness of Three Different Intervention Methods in Patients with Chronic Orofacial Pain: A Randomized, Controlled Clinical Trial | |
| AU2022902326A0 (en) | Formulations for radiotherapy and diagnostic imaging and use thereof in treatment, diagnosis and imaging diseases | |
| Wood | New evidence for a pathogenic link between rosacea and Parkinson disease | |
| Anagnostou et al. | Pharmacokinetic interactions of selective serotοnin reuptake inhibitors |